07:51 AM EDT, 05/16/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday it received European Commission approval for the perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo to treat resectable non-small cell lung cancer.

The approval covers treatment of cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression greater than or equal to 1%, the company said.